NASDAQ:ALLKAllakos Stock Price, Forecast & News

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK shares have increased by 14.8% and is now trading at $66.90. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Allakos.

Allakos Inc (NASDAQ:ALLK) issued its earnings results on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.01. View Allakos' earnings history.

3 analysts have issued 1-year target prices for Allakos' stock. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' share price to reach $65.00 in the next twelve months. This suggests that the stock has a possible downside of 2.8%. View analysts' price targets for Allakos.

News coverage about ALLK stock has trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Allakos.

Allakos saw a drop in short interest in June. As of June 15th, there was short interest totaling 6,820,000 shares, a drop of 7.3% from the May 31st total of 7,360,000 shares. Based on an average trading volume of 354,600 shares, the short-interest ratio is presently 19.2 days. Approximately 27.3% of the shares of the company are short sold. View Allakos' Current Options Chain.

Some companies that are related to Allakos include GRIFOLS S A/S (GRFS), Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC) and Jazz Pharmaceuticals (JAZZ). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), Advanced Micro Devices (AMD), Ascendis Pharma A/S (ASND) and Autolus Therapeutics (AUTL).

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $66.90.

Allakos has a market capitalization of $3.26 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]